The implementation of this policy has brought unprecedented changes to the pharmaceutical industry. It seems that the so-called "purchasing with quantity" in some provinces and cities in front is simply playing house. From the implementation level, it basically exceeded the psychological expectations of all participants.
What changes has he brought? First of all, it marks that the consistency evaluation has entered the normal state. If it is overestimated, it may not win the bid, but if it is not overestimated, there will be no market. Secondly, the high-margin era of original drug research will gradually pass. Simply put, according to logic, passing the consistency evaluation means that it has the same curative effect as the original drug in all aspects, so expired patented drugs should be compared with generic drugs.
More importantly, as mentioned above, the varieties of pharmaceutical companies have to be evaluated before they have prospects, and the investment in consistency evaluation is also high. A variety should be at least 500-600W W W. If it doesn't win the bid after evaluation, it means there is no market, and winning the bid at a low price is a test of cost control.
The profit margin of generic drugs is getting smaller and smaller, and enterprises are forced to make innovative drugs. Only large pharmaceutical companies with strong innovation ability can stand out in the future competition.
For patients, of course, it is a good thing, and the price of drugs has dropped. For example, in Entecavir on sunny days, the price of 4+7 is reduced by more than 90%. At present, it is only 17 yuan in 4+7 cities.
The pharmaceutical industry is an important part of China's national economy, and it is an industry that combines traditional industries with modern industries and integrates primary, secondary and tertiary industries.
Its main categories include: chemical raw materials and preparations, Chinese herbal medicines, Chinese herbal pieces, Chinese patent medicines, antibiotics, biological products, biochemical drugs, radioactive drugs, medical devices, sanitary materials, pharmaceutical machinery, packaging materials and pharmaceutical business.
The pharmaceutical industry plays a very important role in protecting and improving people's health, improving the quality of life, family planning, disaster relief and epidemic prevention, military supplies and war preparedness, and promoting economic development and social progress.
Legal basis: Article 3 of the Implementation Opinions of the State on Organizing Centralized Drug Purchase and Use Pilot to Expand Regional Scope: First, purchase by quantity, and exchange price by quantity. According to 50%-70% of the total annual drug consumption of all public medical institutions, military medical institutions and designated medical institutions with voluntary social medical insurance in the alliance area, the total purchase amount is calculated and the purchase price is formed. Relevant medical institutions or their representatives sign purchase and sale contracts with selected enterprises. The second is to recruit and adopt together to ensure use. Relevant medical institutions in the alliance area give priority to the use of selected drugs, and complete the contract dosage within the agreement period according to the purchase and sale contract with quantity. The third is to give priority to quality and ensure supply. The selected enterprises are the first responsible persons to ensure the quality and supply, and relevant departments should strengthen the whole chain quality supervision and production and inventory monitoring to ensure the quality and supply of drugs. The fourth is to ensure payment back and reduce transaction costs. As the first responsible person for drug payment settlement, medical institutions should settle accounts with enterprises in a timely manner according to the provisions of the contract to reduce the transaction costs of pharmaceutical companies. Strictly investigate the problem that medical institutions do not settle drug fees on time. The document adheres to the supporting convergence policy of the State Council [2065438+09] No.2 document, forming a policy synergy of "three medical services linkage": First, explore the synergy between the medical insurance payment standard and the purchase price in pilot cities, and in principle adopt the same medical insurance payment standard for the original drug under the same generic name and the generic drug that has passed the consistency evaluation. The second is to change birds in cages, promote the reform of public medical institutions, and allow public hospitals to use the balance formed by selected drugs for the salaries of medical staff. The third is to encourage hospitals to use selected drugs with high quality and low price, strengthen performance appraisal and publicity and training for hospitals and medical staff, promote scientific and rational drug use, and ensure the safety of patients' drug use. During the period of 1 -3 years, the platform can purchase other net-hanging varieties with appropriate prices, and the number of manufacturers of the same variety who have passed the consistency evaluation, and the varieties that have not passed the consistency evaluation are no longer selected for centralized drug procurement.